Assembly Biosciences Inc
NASDAQ:ASMB

  • LAST PRICE
    16.5700
  • TODAY'S CHANGE (%)
    0.1600 (0.9750%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    16.2700 / 16.4100
  • Day Range
    16.0000
    16.7050
  • 52 Week Range
    7.6920
    19.9300
  • Volume
    19,048

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:34PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: ASMB
      04:34 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: ASMB
      ---------- --------- Deferred revenue from a related party - long-term 32,511 55,379 Operating lease liabilities - long-term 113 1,122 Total liabilities 74,259 95,726 ---------- --------- Commitments and contingencies Stockholders' equity Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding -- -- Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 6,354,414 and 5,482,752 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 6 5 Additional paid-in capital 841,743 826,921 Accumulated other comprehensive loss (156) (81) Accumulated deficit (815,590) (785,748) Total stockholders' equity 26,003 41,097 ---------- --------- Total liabilities and stockholders' equity $ 100,262 $ 136,823 ========== ========= ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands except for share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ------------------------ 2024 2023 2024 2023 --------- --------- --------- --------- Collaboration revenue from a related party $ 6,845 $ -- $ 21,163 $ -- Operating expenses Research and development 13,515 10,824 41,653 37,894 General and administrative 4,286 4,224 13,398 14,201 Total operating expenses 17,801 15,048 55,051 52,095 --------- --------- --------- --------- Loss from operations (10,956) (15,048) (33,888) (52,095) --------- --------- --------- --------- Other income Interest and other income, net 1,343 628 4,452 1,829 Total other income 1,343 628 4,452 1,829 --------- --------- --------- --------- Loss before income taxes (9,613) (14,420) (29,436) (50,266) --------- --------- --------- --------- Income tax expense -- -- 406 -- Net loss $ (9,613) $ (14,420) $ (29,842) $ (50,266) ========= ========= ========= ========= Other comprehensive loss Unrealized gain (loss) on marketable securities 137 50 (75) 528 Comprehensive loss $ (9,476) $ (14,370) $ (29,917) $ (49,738) ========= ========= ========= ========= Net loss per share, basic and diluted $ (1.51) $ (3.29) $ (5.12) $ (11.61) ========= ========= ========= ========= Weighted average common shares outstanding, basic and diluted 6,351,431 4,380,444 5,827,750 4,329,260 ========= ========= ========= =========

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: ASMB
      ---------- --------- Deferred revenue from a related party - long-term 32,511 55,379 Operating lease liabilities - long-term 113 1,122 Total liabilities 74,259 95,726 ---------- --------- Commitments and contingencies Stockholders' equity Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding -- -- Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 6,354,414 and 5,482,752 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 6 5 Additional paid-in capital 841,743 826,921 Accumulated other comprehensive loss (156) (81) Accumulated deficit (815,590) (785,748) Total stockholders' equity 26,003 41,097 ---------- --------- Total liabilities and stockholders' equity $ 100,262 $ 136,823 ========== ========= ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands except for share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ------------------------ 2024 2023 2024 2023 --------- --------- --------- --------- Collaboration revenue from a related party $ 6,845 $ -- $ 21,163 $ -- Operating expenses Research and development 13,515 10,824 41,653 37,894 General and administrative 4,286 4,224 13,398 14,201 Total operating expenses 17,801 15,048 55,051 52,095 --------- --------- --------- --------- Loss from operations (10,956) (15,048) (33,888) (52,095) --------- --------- --------- --------- Other income Interest and other income, net 1,343 628 4,452 1,829 Total other income 1,343 628 4,452 1,829 --------- --------- --------- --------- Loss before income taxes (9,613) (14,420) (29,436) (50,266) --------- --------- --------- --------- Income tax expense -- -- 406 -- Net loss $ (9,613) $ (14,420) $ (29,842) $ (50,266) ========= ========= ========= ========= Other comprehensive loss Unrealized gain (loss) on marketable securities 137 50 (75) 528 Comprehensive loss $ (9,476) $ (14,370) $ (29,917) $ (49,738) ========= ========= ========= ========= Net loss per share, basic and diluted $ (1.51) $ (3.29) $ (5.12) $ (11.61) ========= ========= ========= ========= Weighted average common shares outstanding, basic and diluted 6,351,431 4,380,444 5,827,750 4,329,260 ========= ========= ========= =========

Peers Headlines